Prognostic significance of the co‑overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer

Murase,Hideaki; Inokuchi,Mikito; Takagi,Yoko; Kato,Keiji; Kojima,Kazuyuki; Sugihara,Kenichi

doi:10.3892/mco.2014.293

Prognostic significance of the co‑overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer

Authors:
- Hideaki Murase
- Mikito Inokuchi
- Yoko Takagi
- Keiji Kato
- Kazuyuki Kojima
- Kenichi Sugihara
View Affiliations

Affiliations: Departments of Surgical Oncology, Tokyo Medical and Dental University, Tokyo 113‑8519, Japan, Department of Translational Oncology, Tokyo Medical and Dental University, Tokyo 113‑8519, Japan, Department of Minimally Invasive Surgery, Tokyo Medical and Dental University, Tokyo 113‑8519, Japan
Published online on: May 15, 2014 https://doi.org/10.3892/mco.2014.293
Pages: 509-517

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The overexpression of fibroblast growth factor receptor (FGFR) 2 is an established prognostic factor and treatment target in gastric cancer. However, the roles of other FGFRs have not been fully elucidated. In this study, we investigated the correlations of the expression of FGFR1‑4 with clinicopathological characteristics and outcomes in gastric cancer. Tumor samples were obtained from 222 patients with gastric adenocarcinoma who underwent gastrectomy between 2003 and 2007. The expression of each FGFR was measured in the tumors by immunohistochemical analysis. The overexpression of FGFR1, FGFR2 or FGFR4 was found to be significantly associated with tumor progression, including depth of invasion, lymph node metastasis, pathological stage and distant metastasis or recurrent disease. Patients exhibiting overexpression of FGFR1, FGFR2 or FGFR4 had a significantly poorer disease‑specific survival (DSS; P<0.001, P=0.008 and P<0.001, respectively). Moreover, the co‑overexpression of all three FGFRs was significantly associated with a poorer DSS compared to the expression of none or only one of the FGFRs (P<0.001 and P=0.001, respectively) and it was found to be an independent prognostic factor (HR=1.71, 95% CI: 1.02‑2.85, p=0.041). In conclusion, high expression of FGFR1, FGFR2 or FGFR4 was associated with tumor progression and poor survival in patients with gastric cancer. Similar to FGFR2, FGFR1 and FGFR4 may be considered as prognostic factors and treatment targets in gastric cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Brenner H, Rothenbacher D and Arndt V: Epidemiology of stomach cancer. Methods Mol Biol. 472:467–477. 2009. View Article : Google Scholar
3	Hartgrink HH, Jansen EP, van Grieken NC and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009. View Article : Google Scholar
4	Cunningham D, Starling N, Rao S, et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
5	Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar
6	Gravalos C and Jimeno A: HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 19:1523–1529. 2008. View Article : Google Scholar : PubMed/NCBI
7	Hofmann M, Stoss O, Shi D, et al: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 52:797–805. 2008. View Article : Google Scholar : PubMed/NCBI
8	Kimelman D and Kirschner M: Synergistic induction of mesoderm by FGF and TGF-beta and the identification of an mRNA coding for FGF in the early Xenopus embryo. Cell. 51:869–877. 1987. View Article : Google Scholar : PubMed/NCBI
9	De Moerlooze L, Spencer-Dene B, Revest JM, Hajihosseini M, Rosewell I and Dickson C: An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development. 127:483–492. 2000.PubMed/NCBI
10	Turner N and Grose R: Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 10:116–129. 2010. View Article : Google Scholar : PubMed/NCBI
11	Kunii K, Davis L, Gorenstein J, et al: FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 68:2340–2348. 2008. View Article : Google Scholar : PubMed/NCBI
12	Toyokawa T, Yashiro M and Hirakawa K: Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma. Oncol Rep. 21:875–880. 2009.PubMed/NCBI
13	Zhao WM, Wang L, Park H, et al: Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts. Clin Cancer Res. 16:5750–5758. 2010. View Article : Google Scholar : PubMed/NCBI
14	Zhao G, Li WY, Chen D, et al: A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther. 10:2200–2210. 2011. View Article : Google Scholar
15	Brooks AN, Kilgour E and Smith PD: Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 18:1855–1862. 2012. View Article : Google Scholar : PubMed/NCBI
16	Shin EY, Lee BH, Yang JH, et al: Up-regulation and co-expression of fibroblast growth factor receptors in human gastric cancer. J Cancer Res Clin Oncol. 126:519–528. 2000. View Article : Google Scholar : PubMed/NCBI
17	Oki M, Yamamoto H, Taniguchi H, Adachi Y, Imai K and Shinomura Y: Overexpression of the receptor tyrosine kinase EphA4 in human gastric cancers. World J Gastroenterol. 14:5650–5656. 2008. View Article : Google Scholar : PubMed/NCBI
18	Ye Y, Shi Y, Zhou Y, et al: The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression. Ann Surg Oncol. 17:3354–3361. 2010. View Article : Google Scholar : PubMed/NCBI
19	Ye YW, Zhou Y, Yuan L, et al: Fibroblast growth factor receptor 4 regulates proliferation and antiapoptosis during gastric cancer progression. Cancer. 117:5304–5313. 2011. View Article : Google Scholar : PubMed/NCBI
20	Eswarakumar VP, Lax I and Schlessinger J: Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16:139–149. 2005. View Article : Google Scholar : PubMed/NCBI
21	Vainikka S, Joukov V, Wennström S, Bergman M, Pelicci PG and Alitalo K: Signal transduction by fibroblast growth factor receptor-4 (FGFR-4). Comparison with FGFR-1. J Biol Chem. 269:18320–18326. 1994.PubMed/NCBI
22	Wang JK, Gao G and Goldfarb M: Fibroblast growth factor receptors have different signaling and mitogenic potentials. Mol Cell Biol. 14:181–188. 1994.PubMed/NCBI
23	Shaoul E, Reich-Slotky R, Berman B and Ron D: Fibroblast growth factor receptors display both common and distinct signaling pathways. Oncogene. 10:1553–1561. 1995.PubMed/NCBI
24	Xian W, Schwertfeger KL and Rosen JM: Distinct roles of fibroblast growth factor receptor 1 and 2 in regulating cell survival and epithelial mesenchymal transition. Mol Endocrinol. 21:987–1000. 2007. View Article : Google Scholar : PubMed/NCBI
25	Turner N, Pearson A, Sharpe R, et al: FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70:2085–2094. 2010. View Article : Google Scholar
26	Theillet C, Adelaide J, Louason G, et al: FGFRI and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chromosomes Cancer. 7:219–226. 1993. View Article : Google Scholar : PubMed/NCBI
27	Simon R, Richter J, Wagner U, et al: High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res. 61:4514–4519. 2001.PubMed/NCBI
28	Weiss J, Sos ML, Seidel D, et al: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2:62ra932010.PubMed/NCBI
29	Sato T, Oshima T, Yoshihara K, et al: Overexpression of the fibroblast growth factor receptor-1 gene correlates with liver metastasis in colorectal cancer. Oncol Rep. 21:211–216. 2009.PubMed/NCBI
30	Sugiura K, Ozawa S, Kitagawa Y, Ueda M and Kitajima M: Co-expression of aFGF and FGFR-1 is predictive of a poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep. 17:557–564. 2007.PubMed/NCBI
31	Bange J, Prechtl D, Cheburkin Y, et al: Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 62:840–847. 2002.PubMed/NCBI
32	Thussbas C, Nahrig J, Streit S, et al: FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol. 24:3747–3755. 2006. View Article : Google Scholar : PubMed/NCBI
33	Marmé F, Hielscher T, Hug S, et al: Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer. Int J Cancer. 131:E586–E591. 2012.PubMed/NCBI
34	Frullanti E, Berking C, Harbeck N, et al: Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor. Eur J Cancer Prev. 20:340–347. 2011. View Article : Google Scholar : PubMed/NCBI
35	Leung HY, Gullick WJ and Lemoine NR: Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int J Cancer. 59:667–675. 1994. View Article : Google Scholar : PubMed/NCBI
36	Takahashi A, Sasaki H, Kim SJ, et al: Identification of receptor genes in renal cell carcinoma associated with angiogenesis by differential hybridization technique. Biochem Biophys Res Commun. 257:855–859. 1999. View Article : Google Scholar : PubMed/NCBI
37	Hattori Y, Odagiri H, Nakatani H, et al: K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. Proc Natl Acad Sci USA. 87:5983–5987. 1990. View Article : Google Scholar : PubMed/NCBI
38	Heiskanen M, Kononen J, Bärlund M, et al: CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors. Anal Cell Pathol. 22:229–234. 2001. View Article : Google Scholar : PubMed/NCBI
39	Jang JH, Shin KH and Park JG: Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 61:3541–3543. 2001.PubMed/NCBI
40	Davies H, Hunter C, Smith R, et al: Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 65:7591–7595. 2005.PubMed/NCBI
41	Byron SA, Gartside MG, Wellens CL, et al: FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecol Oncol. 117:125–129. 2010. View Article : Google Scholar : PubMed/NCBI
42	Pollock PM, Gartside MG, Dejeza LC, et al: Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene. 26:7158–7162. 2007. View Article : Google Scholar
43	Gartside MG, Chen H, Ibrahimi OA, et al: Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res. 7:41–54. 2009. View Article : Google Scholar : PubMed/NCBI
44	Hattori Y, Itoh H, Uchino S, et al: Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res. 2:1373–1381. 1996.PubMed/NCBI
45	Nord H, Segersten U, Sandgren J, et al: Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma. Int J Cancer. 126:1390–1402. 2010.PubMed/NCBI
46	Khnykin D, Troen G, Berner JM and Delabie A: The expression of fibroblast growth factors and their receptors in Hodgkin’s lymphoma. J Pathol. 208:431–438. 2006.
47	Rosty C, Aubriot MH, Cappellen D, et al: Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation. Mol Cancer. 4:152005. View Article : Google Scholar : PubMed/NCBI
48	Hernández S, de Muga S, Agell L, et al: FGFR3 mutations in prostate cancer: association with low-grade tumors. Modern Pathol. 22:848–856. 2009.PubMed/NCBI
49	Goriely A, Hansen RMS, Taylor IB, et al: Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. Nat Genet. 41:1247–1252. 2009. View Article : Google Scholar : PubMed/NCBI
50	van Oers JM, Wild PJ, Burger M, et al: FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol. 52:760–768. 2007.
51	Mhawrech-Fauceglia P, Cheney RT, Fischer G, Beek A and Herrmann FR: FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol. 32:231–237. 2006. View Article : Google Scholar : PubMed/NCBI
52	Qiu WH, Zhou BS, Chu PGG, et al: Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. World J Gastroenterol. 11:5266–5272. 2005.PubMed/NCBI
53	Kuroso K, Imai Y, Kobayashi M, et al: Immunohistochemical detection of fibroblast growth factor receptor 3 in human breast cancer: correlation with clinicopathological/molecular parameters and prognosis. Pathobiology. 77:231–240. 2010. View Article : Google Scholar
54	Katoh M and Nakagama H: FGF receptors: cancer biology and therapeutics. Med Res Rev. 34:280–300. 2013. View Article : Google Scholar : PubMed/NCBI
55	Qiu H, Yashiro M, Zhang X, Miwa A and Hirakawa K: A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells. Cancer Lett. 307:47–52. 2011. View Article : Google Scholar : PubMed/NCBI
56	Xie L, Su X, Zhang L, et al: FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res. 19:2572–2583. 2013. View Article : Google Scholar : PubMed/NCBI